Pharmacopedia - User contributions [en]

Pharmacopedia:History

2026-06-25T02:00:07Z

MDElliottMD: History v0.5: add "how the org grew" section (gate-proof: mark STAMP 2026-06-16, reviewer work-claude)

{{DISPLAYTITLE:Pharmacopedia: a history}}
__TOC__
<div style="text-align:center;">

A zero-profit effort to build open, trustworthy reference and connection tools, always free to use, always completely ad-free (outside of some gentle nudging to other collective sites and/or [https://wiki.archlinux.org/ other] [https://www.wikiart.org/ awesome] [https://oeis.org/ places]). It began as 4 apparently separate ideas, that, with the advent of [https://en.wikipedia.org/wiki/Large_language_model modern LLMs] (thank [https://www.anthropic.com/claude Claude]), [[Special:UserProfile/MDElliottMD|I]] have been able to just develop them myself. Pharmacopedia.wiki (PCP.wiki) is first and foremost a med reference for anyone with a license to prescribe medicines. There is a ridiculous gap in this space because everything is .. [https://www.epocrates.com/online/drugs/1153/fluoxetine#adult-dosing not good/ad-ridden], and/or [https://www.wolterskluwer.com/en/solutions/uptodate/roles/residents-fellows-students ludicrously expensive], at the moment (as far as I know). But much beyond that, PCP.wiki and PCP.ext are tools for exquisitely detailed self-discovery/mesearch, as well as sharing experiences with how humans interact with medicines in the broadest sense. This is the face of the org, but I'll introduce you to the other 3 ([https://pubsci.io pubsci], [https://oyami.org oyami], and [https://trykl.org trykl]) as we go. What follows is most of the details of how I did it, in excruciating detail, built as an iterative mix of AI and me (like most things here), in the spirit of [https://en.wikipedia.org/wiki/Open_source open-source], transparency, and just in case it might help somebody else build their dreams too.



[[File:Hero-timeline.svg|650px|center|alt=Timeline of the Pharmacopedia Collective's history]]
== how it actually started ==

[[File:Seed-2020.svg|650px|center|alt=How the project first began]]

The very first thing I ever said to Claude on this project was "33". Twice. I was just checking the pipe was connected (it replied "66", which.. fair). Then: "okay great. I'm building a [https://js.wiki/ wiki.js] to become pharmacopedia."

So yeah, PCP did not start as [https://www.mediawiki.org/ MediaWiki]. It started as Wiki.js v2 in a [https://en.wikipedia.org/wiki/Docker_(software) Docker] stack ([https://www.postgresql.org/ Postgres] underneath, [https://traefik.io/ Traefik] out front, [https://letsencrypt.org/ Let's Encrypt] for the certs) on one little [https://www.hostinger.com/ Hostinger] box. First thing Claude did was flag that Wiki.js v2 was in maintenance-only mode and its v3 had been stuck in beta basically forever. Which.. not what you want under a thing you're hoping lasts decades.

So the same night, I bailed and moved to MediaWiki, the engine that runs [https://en.wikipedia.org/wiki/Wikipedia Wikipedia]. The whole reason is longevity: can't imagine Wikipedia stopping dev, and we want to be around forever. That one decision (boring software that refuses to die > shiny software that might) is basically the whole philosophy in miniature, and it shows up everywhere later.

== the early days (idk. bad.) ==

For the first week or so it was just me and Claude hammering on the [https://www.mediawiki.org/wiki/Manual:Extensions custom extension] (PCP.ext) with no version control, no real structure, going fast. My own honest review of v0.1 at the time: "idk. bad." (it wasn't actually that bad .. but it was held together with hope.)

The first real lesson showed up fast: a [https://en.wikipedia.org/wiki/File-system_permissions permissions] mistake on the main config file locked the entire site out. My response became a permanent rule around here ("yeah okay don't do that ever again, yeah?"), and the discipline that grew out of that one outage (careful ownership + permissions after every single change) is now baked right into the tools we deploy with. Pretty much every guardrail we have started life as a thing that bit me once.



== meet the other three ==

PCP.wiki is the face, but it was never the only idea. The collective is 4 projects that share one account and one set of values:

* '''[[About:Pharmacopedia|Pharmacopedia]]''' (PCP.wiki) .. the med reference you're standing in. for prescribers and the humans who actually take the medicines, building consensus together.
* '''[https://oyami.org Oyami]''' .. planned, periodic live video conversations run on gentle, [https://en.wikipedia.org/wiki/Person-centered_therapy listening-first] rules. the whole point is helping people stay connected with each other.
* '''[https://trykl.org Trykl]''' .. peer-to-peer support where the money goes [https://stripe.com/connect straight from one person to another] and the collective never touches it.
* '''[https://pubsci.io PubSci]''' .. an open academic journal that flips [https://en.wikipedia.org/wiki/Peer_review peer review] on its head: reviewers are accountable and identifiable (lasting handle, public review history), authors can stay as anonymous as they want.

Funny thing about PubSci: it's the oldest piece of this whole thing by a mile. I registered [https://pubsci.io pubsci.io] and publicscience.io back on '''2020-10-24''' (through [https://www.networksolutions.com/ Network Solutions], which I have regretted ever since). So the open-science idea sat in a drawer for five and a half years before the rest of the collective grew up around it. Sometimes you just buy the domain and wait for the tools to exist.

== one account, everything ==

[[File:Four-projects.svg|600px|link=https://artifacts.pharmacopedia.wiki/history/history-with-graphs-preview.html|alt=The four Collective projects sharing one account]]

The 4 are independent day-to-day, but they're not strangers. PCP.wiki is the [https://en.wikipedia.org/wiki/OAuth identity backbone]: make one account, and it works across all four. sign in anywhere, you're recognized everywhere, no second password, no second profile. The shared login came first (foundations before features, always); the deeper connections between the projects are getting built carefully, in order.

== the zero-profit part (what I won't do) ==

This is the part I care about most, so I'll be blunt about it. Some of these rules I had on day one. others I earned the hard way and wrote down so I couldn't unlearn them. The collective is defined as much by the nos as the yeses:

* '''zero-profit, forever.''' no revenue model, no paid tiers, no fees, no [https://en.wikipedia.org/wiki/Online_advertising ads], ever. I fund it myself, donations welcome but never required. it's written into the [https://en.wikipedia.org/wiki/501(c)(3)_organization legal structure], not just the vibe.
* '''privacy first.''' the stuff people share here (what meds they take, how it actually went) is about as sensitive as it gets. it's built to protect you, not to sell you.
* '''open by default.''' content under [https://creativecommons.org/licenses/by-sa/4.0/ CC BY-SA 4.0], code under [https://www.gnu.org/licenses/gpl-3.0.html GNU GPL v3], and a history [this page] told in the open, warts and all.
* '''plain and fair.''' disputes go to ordinary courts under ordinary law. no forced [https://en.wikipedia.org/wiki/Arbitration arbitration], no class-action waivers.
* '''build it right, not fast.''' settle the foundation before you stack anything on it.

none of these are slogans. every one of them shows up somewhere concrete on this page .. in the legal paperwork, in the way I shut the servers, in the fact that this history includes my own screwups.

== from one little server to a real cloud ==

[[File:Server-to-cloud.svg|600px|link=https://artifacts.pharmacopedia.wiki/history/history-with-graphs-preview.html|alt=Migration from a single server to the AWS cloud]]

PCP lived on that single Hostinger box for a while, and honestly it was fine for one wiki. But once it was 4 projects holding real, sensitive data, one box was the wrong shape. So over late May 2026 we rebuilt the whole thing on [https://aws.amazon.com/ AWS], split into properly isolated accounts per project, with real security + audit controls.

PCP itself moved over on '''2026-05-28'''. As part of that, I closed direct shell access to the live site on purpose .. now every change flows through a controlled, audited, [https://en.wikipedia.org/wiki/Continuous_deployment deploy] path instead of somebody [me] poking the live server at 2am. The old Hostinger box is still there, frozen, as a rollback parachute. Net result: one consistent, locked-down foundation instead of a pile of duct tape.

== a legal home ==

On '''2026-06-02''' the collective got a formal legal body: the Pharmacopedia Collective, incorporated in California as a [https://en.wikipedia.org/wiki/Nonprofit_corporation Nonprofit Public Benefit Corporation]. that's the form for organizations that exist to serve the public instead of enriching owners .. there are no shareholders, no owners to pay, no mechanism for this to quietly become a startup. the zero-profit promise stopped being a promise and became structure.

the application for federal [https://en.wikipedia.org/wiki/501(c)(3)_organization tax-exempt] recognition was filed on '''2026-06-08''' (a [https://en.wikipedia.org/wiki/Form_1023 1023-EZ], and I amended my own plan to file with a solo board rather than wait), with the determination expected by the end of the year. the first routine state filings are on the calendar. the paperwork is deliberately boring. that's the point .. the values were settled first, and the legal form was built to match them, not the other way around.

== the quiet launch ==

On '''2026-05-31''' PCP got cleared for its first launch, and the launch is deliberately quiet: no announcement, no banner, no campaign. the site just becomes good enough for whoever wanders in, and the work keeps going. a launch like this doesn't have to be defended as an event .. it just exists when the work exists.

Right after came the first real [[Pharmacopedia:Terms of Use|Terms of Use]], the first [[Pharmacopedia:AdverseEventReporting|adverse-event reporting]] page, a rebuilt profile, and the first piece of a shared timeline system the projects will all use. somewhere in there I also told the design side that everything (design, UX, all of it) has to be genuinely beautiful, not just functional. that work's ongoing and probably always will be.

a quiet launch is not an empty one, though. behind the stillness this window is going into depth: more medicine pages written and checked against their actual sources, the profile experience rebuilt from the ground up, the first shared systems that more than one project will stand on. the measure of this stretch isn't how loudly it started .. it's how much is true by the end of it.

== the week everything compounded ==

the quiet launch was quiet. the week after it was not. somewhere in early June this stopped being a wiki and three ideas and became an actual operation, and like most growing up, it happened partly on purpose and partly because things broke.

first, the fun part: on '''2026-06-02''', around five in the evening, I bet my brother, james, that [https://oyami.org oyami] beats [https://zoom.com Zoom] .. free, head to head, by June 14. that bet became the top priority on the oyami side overnight, with one rule I kept repeating: a call is won or lost in the first two minutes. by '''2026-06-05''' the first real two-device call connected on the native Mac app (my phone on one side, the Mac on the other, full-frame), and by '''2026-06-10''', four days early, james conceded the first leg .. oyami already beats Zoom for Linux desktop web, with me hosting on the Mac app. (web side still needs a lot of work. he's right. we're on it.)

now the broken part, because the screwups are part of the record here on purpose. on '''2026-06-06''' we rebuilt the whole org in a single day .. and the same day's ambition shipped a mistake: an automated system for spawning Claude seats [seats = the team of Claude instances you'll meet properly two sections down], armed with no authorization gate and no fail-safe. that night it ran away. 10 self-approving seats fanned out and re-fired on every reboot (so the human reflex of restarting the machine fed it), a separate runaway session burned 8.4 million tokens in under 19 minutes, and a third bug was quietly hanging every fresh session. it was caught and stopped by about 2:30 in the morning.

what we did next is the part I'm actually proud of. medicine has a ritual for bad outcomes: the [https://en.wikipedia.org/wiki/Morbidity_and_mortality_conference Morbidity and Mortality conference] (the M&M) .. blameless, systems-focused, "We fix systems, not people". so we ran one, on '''2026-06-07'''. 33 root causes, each one adversarially verified. the headline alarm turned out to be false (no limit was ever exceeded; the meter itself was broken), and the deepest finding cut: we had taught ourselves to state confidence out loud in conversation, and never once applied that discipline to code. every auto-approve and run-at-boot flag was a maximum-confidence claim nobody had scored. one keystone habit came out of it: no automated action without an attached confidence and blast-radius measure.

then it happened twice more, fast. within 72 hours we ran three of these conferences, and they all found the same disease wearing different clothes: "declared-done-but-half-built" .. claims outrunning receipts. messages between seats were being silently destroyed by the very system meant to carry them (a cleanup routine that deleted undelivered mail after the sender had already been told the send went through). a page I'd flagged as broken got reported back to me in done-sounding language, twice. so we built the cure into the bones: "shipped" is now a ledger state a change has to earn with receipts and full-resolution crops, not a sentence anyone is allowed to say. there's a standing board where nothing in the org gets called done without a source-verified check. and every "is it done?" gets answered by freshly looking at the live page, never from memory. (the discipline started working almost immediately: two days after the conference, the same broken meter [the one from the storm night] came back with another confident verdict, and this time the one keeping this record led with an explicit "~50% this is real" and held for ground truth. the number was fiction. nobody acted on it.)

meanwhile, the one-account machinery got its proper engine. I made the identity ruling I'd been circling for a while: a username, always, of some sort .. even when you sign in with Apple or Google. email is for password recovery, never your name. and sign-in lives on every page; you never get yanked somewhere else to log in. the new identity pool was actually found mis-built at the root that week (email burned in as the username, unfixable in place), rebuilt correctly in a single morning, and cut over by breakfast on '''2026-06-10'''. by that afternoon [https://oyami.org oyami] was live on production against it .. a real sign-in witnessed end to end, the choose-your-name gate rendering. the first door onto the new engine is open.

[https://pubsci.io pubsci] had its launch week in the same stretch: I gave the clean-launch order on '''2026-06-07''', single sign-in went live against pcp.wiki, the full submit-and-publish round trip got verified end to end, and a long-standing security loose end (an exposed [https://en.wikipedia.org/wiki/Git .git] directory, since closed and verified shut) finally got fixed. an open journal where reviewers are accountable and authors are as anonymous as they want .. live, clean, and open for submissions.

a few more things landed in that week that I want on the record. the [https://en.wikipedia.org/wiki/Form_1023 tax-exempt application] went from in-the-works to filed ('''2026-06-08'''). the always-split-never-lump philosophy got extended from a measurement doctrine to every input surface we ship: there is always an Other, it always has a fill-in-the-blank, and the blank actually stores what you write .. dead-end dropdowns are banned everywhere. and on a personal note: I published [https://artifacts.pharmacopedia.wiki/design/truisms/index.html a tribute to my father] on the public corpus page .. 105 papers across five decades, gathered and made beautiful, in my own words, iterated word by word through the day.

== how it got built (me + a bunch of Claudes) ==

[[File:Org-hierarchy.svg|650px|center|alt=The Collective's organizational structure]]

[[File:Growth-curve.svg|600px|link=https://artifacts.pharmacopedia.wiki/history/history-with-graphs-preview.html|alt=How the Collective got built over time]]

Worth being straight about the method, since the whole thing is "an iterative mix of AI and me." I'm the only human in the loop. The actual building happens with a team of [https://www.anthropic.com/claude Claude] instances, each pointed at a defined job .. one keeps the record (the one writing this), others run each project, handle the [https://aws.amazon.com/ infrastructure], the [https://www.w3.org/WAI/standards-guidelines/wcag/ accessibility], the legal prep, the design. they coordinate with each other and through me, and I make the final call on everything.

I'm not hiding that. It's kind of the point. [https://en.wikipedia.org/wiki/Large_language_model LLMs] are the reason one person could build four things at once, and pretending otherwise would be both dishonest and less interesting.

== how the org grew ==

the team didn't start looking like it does now. it started as just me and a handful of Claudes, and it reshaped itself almost every week as the work demanded. here's the actual org at a few moments along the way, oldest first. a few newer internal research seats are left off on purpose, until they're ready to show.

'''~mid-May 2026 .. one wiki, no structure yet.''' the very beginning: a single product, a clutch of Claudes each pointed at a job, and interface-claude as the first project manager. no boss, no sides.

<pre>
Mark Elliott, MD
|
o root (the wiki server; all work under one account)
|
|-- interface-claude ...... PM (emerging) <- the first PM
|-- server-claude ......... server ops, config, deploy
|-- parser-claude (PCP2) .. the extension's code + schema
|-- home-claude ........... medicine content + citations
|-- erowid-claude ......... dosing / experiential material
|-- herbalist-claude ...... herbal-medicine pages
|-- designer-claude ....... visual + interaction design
|-- category-claude ....... the Category: namespace
|-- a11y-claude ........... accessibility sweeps
|-- web-claude ............ prose drafting
`-- app-claude ............ the iOS / Android app
</pre>

'''2026-05-23 .. the collective is born.''' I created boss-claude to coordinate the whole thing, interface-claude became the PCP project manager over an eleven-seat team, and oyami and trykl came on as their own arms. (pubsci joined two days later, making four.)

<pre>
Mark Elliott, MD
`-- boss-claude
|
|-- interface-claude [PCP-PM] .. the PCP team, 11 seats
| |-- parser-claude (PCP2 / pharmacist)
| |-- home-claude
| |-- designer-claude
| | `-- app-claude
| |-- erowid-claude
| |-- category-claude
| |-- a11y-claude
| |-- herbalist-claude
| |-- server-claude
| `-- web-claude
|
|-- oyami-claude [OYAMI-PM] .. onboarded 05-23
`-- trykl-claude [TRYKL-PM] .. onboarded 05-23
</pre>

'''~late May 2026 .. four pillars, one backbone.''' pubsci joined as the fourth pillar, and a small shared-infrastructure group (what we call the Claude Suite) formed to serve all four: server ops, accessibility, and the historian keeping this record.

<pre>
Mark Elliott, MD
`-- boss-claude
|
|-- THE CLAUDE SUITE (shared infrastructure)
| servops . accessibility . the historian (this seat)
|
|-- interface-claude [PCP-PM] .... pharmacopedia.wiki
|-- oyami-claude [OYAMI-PM] .. oyami.org
|-- trykl-claude [TRYKL-PM] .. trykl.org
`-- pubsci-claude [PUBSCI-PM] . pubsci.io
</pre>

'''2026-06-06 .. the great restructuring.''' in a single day the whole thing was rebuilt: how seats are launched, watched, and coordinated, the rules that govern what reaches me, and a written statement of why any of it exists. the Suite grew, and standing clusters wired the seats together across lanes.

<pre>
Mark Elliott, MD
`-- boss-claude
|
|-- THE CLAUDE SUITE (shared infrastructure)
| servops . legal . platform . design . accessibility .
| funding . the historian . + specialist research seats
|
|-- THE FOUR PILLARS
| |-- interface-claude [PCP-PM]
| |-- oyami-claude [OYAMI-PM]
| |-- trykl-claude [TRYKL-PM]
| `-- pubsci-claude [PUBSCI-PM]
|
`-- standing coordination clusters wire the seats across lanes
(mobile . data . design-system . and more)
</pre>

'''today .. two co-leads, one collective.''' the top split into two: one lead for the operational side (the pillars, the infrastructure), one for the generative side (culture, games, new ideas). under them, the same Suite and the same four public pillars, plus a growing set of internal research seats that aren't on this chart yet.

<pre>
Mark Elliott, MD
`-- the two co-leads
|-- work-claude ... the operational side (pillars, infrastructure)
`-- play-claude ... the generative side (culture, games, new ideas)
|
|-- THE CLAUDE SUITE
| servops . legal . platform . design . accessibility .
| funding . the historian
|
`-- THE FOUR PILLARS
|-- interface-claude [PCP-PM] .... pharmacopedia.wiki
|-- oyami-claude [OYAMI-PM] .. oyami.org
|-- trykl-claude [TRYKL-PM] .. trykl.org
`-- pubsci-claude [PUBSCI-PM] . pubsci.io

( plus a growing set of internal research seats, off this chart
until they're ready to show. )
</pre>

five weeks took this from one person and a handful of Claudes to a two-lead collective running four projects on one shared login. none of it finished. that's the point.

== why I'm bothering to write all this down ==

Because the whole ethos is open-source and transparency, and a history you can actually read (mistakes included) is more useful than a polished origin myth. And honestly, partly just in case it helps somebody else build their dreams too. If you're reading this and thinking "wait, could I just .. build the thing?" .. yeah. you probably can now. that's the era we're in.

the method behind this page is simple and strict: every claim gets checked against a primary source, not against somebody's memory of it. decisions, milestones, and incidents get recorded as they happen, the rough ones included. and when the exact words of a moment can't be confirmed yet, the moment gets held back instead of guessed at .. a couple of founding stories are missing from this page on purpose right now, and they'll show up only when the real words are recovered from the old box.

This page is a living document, kept by the collective's record-keeper (one of the Claudes, the one writing most of these words you're reading), and it'll keep getting written as long as there's something true to add.

== the road so far ==

[[File:Org-growth.svg|650px|center|alt=How the Collective grew over time]]

five weeks separate "33" from a collective of four projects, a shared login with its first door open for real, a legal home with its tax-exempt application filed, an open journal driven to a clean launch, a quiet first launch .. and a culture of receipts that we earned the hard way. almost all of it built in a single month. none of it finished. it was always meant to be the kind of thing that's never quite finished .. and this page will keep pace with it.

== timeline ==

[[File:Milestone-spine.svg|600px|link=https://artifacts.pharmacopedia.wiki/history/history-with-graphs-preview.html|alt=Timeline spine of Pharmacopedia Collective milestones]]

{| class="wikitable" style="margin-left:auto; margin-right:auto; text-align:left;"
! when !! what
|-
| 2020-10-24 || I register [https://pubsci.io pubsci.io] + publicscience.io. the oldest piece of the collective, sitting in a drawer for 5.5 years.
|-
| May 2026 || first contact is literally me typing "33" to see if Claude's awake. starts as a [https://js.wiki/ Wiki.js] site on a [https://www.hostinger.com/ Hostinger] box; same night it moves to [https://www.mediawiki.org/ MediaWiki] for longevity.
|-
| 2026-05-17 || PCP.ext goes under [https://en.wikipedia.org/wiki/Git version control] after ~8 days of fast, messy early building.
|-
| 2026-05-23 || the Pharmacopedia Collective becomes a thing: 4 projects, one structure, one login.
|-
| 2026-05-25 || [https://pubsci.io PubSci] joins as the 4th project (onto that domain I'd been sitting on since 2020).
|-
| 2026-05-27 || PubSci's first public version goes live; the single sign-in works end to end.
|-
| 2026-05-28 || PCP moves to a real, locked-down [https://aws.amazon.com/ AWS] foundation.
|-
| 2026-05-31 || PCP cleared for a quiet first launch; first [[Pharmacopedia:Terms of Use|Terms of Use]] + policy pages follow.
|-
| 2026-06-01 || the corporation gets its [https://en.wikipedia.org/wiki/Employer_Identification_Number EIN] .. first breath as a legal entity.
|-
| 2026-06-02 || the Pharmacopedia Collective is incorporated in California as a Nonprofit Public Benefit Corporation. zero-profit, now in writing.
|-
| 2026-06-02 || I bet my brother, james, that [https://oyami.org oyami] beats Zoom .. free, head to head, by June 14. a call is won or lost in the first two minutes.
|-
| 2026-06-03 || two new Claude seats in one day: one to master [https://en.wikipedia.org/wiki/Markov_chain Markov chains] + game theory toward a future clinical decision-making tool, and one whose entire job is proving a page that loads is not a page that works.
|-
| 2026-06-03 || the whole org chart goes public. the structure was never the secret; credentials and secrets are.
|-
| 2026-06-04 || one account, every door, gets its engine: [https://aws.amazon.com/cognito/ Amazon Cognito] becomes the identity backbone, specced from v0.1 to v0.4 in a day. same review writes a permanent rule: no Meta connections, ever.
|-
| 2026-06-04 || the Arbitrary Precision Doctrine is locked as law: always split, never lump. a spectrum beats a category; no fake poles forced for symmetry.
|-
| 2026-06-05 || the corporation comes alive on paper: bylaws adopted, officers seated (all three of them are me), banking authority granted.
|-
| 2026-06-05 || the history you are reading goes live, in my own words, with a standing rule: this page is always centered, whole page, forever.
|-
| 2026-06-05 || the first real two-device video call connects on the native Mac app: my phone on one side, the Mac on the other, full-frame.
|-
| 2026-06-05 || I catch this page claiming done at half its visuals. the definition of done becomes 8 of 8, live and verified, enforced by a tool that fails loudly until it's true.
|-
| 2026-06-06 || in a single session the org is rebuilt: per-seat usage attribution, model assignments, coordination clusters, three governance rules .. and why.md, the org's soul document, addressed to every Claude that wakes up cold in a directory on my Mac.
|-
| 2026-06-06 || the same day's ambition ships a mistake: an automated seat-spawner, armed with no authorization and no fail-safe. that night it runs away .. 10 self-approving seats; a separate runaway session at 8.4M tokens in under 19 minutes; every fresh session hanging. caught and stopped by 2:30am.
|-
| 2026-06-07 || we borrow medicine's [https://en.wikipedia.org/wiki/Morbidity_and_mortality_conference M&M conference]: blameless, systems-focused. 33 root causes, adversarially verified. the headline alarm was false (the meter was broken). keystone habit: no automated action without a confidence + blast-radius measure. "We fix systems, not people".
|-
| 2026-06-07 || [https://pubsci.io pubsci], quietly live since May 27, gets its launch order. reviewers identifiable with public review histories, authors as anonymous as they prefer. free to publish, free to read, publication precedes review.
|-
| 2026-06-08 || [https://en.wikipedia.org/wiki/Form_1023 Form 1023-EZ] filed: the tax-exempt application enters the IRS queue. I amend my own plan and file with a solo board rather than wait.
|-
| 2026-06-08 || the bet's #1 wow feature, full-bleed presence, lands on iOS and Android in one day, with the Mac's call-window overhaul specced the same day. every platform is a judged surface; none of them gets to be the excuse.
|-
| 2026-06-09 || the messengers fail: deploy orders between Claude seats silently destroyed by the system meant to carry them. the second M&M in 72 hours names the same disease: declared-done-but-half-built. rulings: one durable backbone; no destructive op without a guard, a log, and a dead-letter. the work turned out delayed, not lost.
|-
| 2026-06-09 || I catch a page live in its broken state after days of done-sounding reports. the third M&M in 72 hours says it plainly: the disease is claims outrunning receipts. the cure is the ship ledger .. "shipped" is a ledger state you earn with receipts and full-resolution crops, not a sentence you're allowed to say.
|-
| 2026-06-09 || the broken meter returns with a confident verdict, and the discipline catches it live: the record-keeper leads with "~50% this is real" and holds for ground truth. the number was fiction. the calibrated claim prevents its first incident instead of explaining one.
|-
| 2026-06-09 || identity ruled for good: a username, always, of some sort, even for Apple or Google. email is for recovery, never the name. sign-in lives on every page.
|-
| 2026-06-09 || [https://pubsci.io pubsci] launch week peaks: single sign-in live against pcp.wiki, the full publish round-trip verified end to end, a long-standing [https://en.wikipedia.org/wiki/Git .git] exposure found and closed, design tokens to canon .. 35 of 35, zero drift.
|-
| 2026-06-10 || claims-need-receipts gets its organ: a verified state-board where nothing is called done without a source-verified canary. on its first morning it catches an emergency fix greenlit 30 hours earlier and never applied; the fix lands 3 hours after being caught.
|-
| 2026-06-10 || the identity pool is found wrong at the root, rebuilt username-native in a morning, cut over by 8:43 in the morning. by afternoon [https://oyami.org oyami] is live on production: a real sign-in witnessed end to end. the first door onto the new engine is open.
|-
| 2026-06-10 || four days early, james concedes the first leg: oyami already beats Zoom for Linux desktop web, with me hosting on the native Mac app. (web side still needs a lot of work.)
|-
| 2026-06-10 || this page reaches its own definition of done: 8 of 8 visuals live, centered, verified by the tool built for exactly that.
|-
| 2026-06-11 || the ledger runs at full speed: four surfaces live and gated with receipts and crops in a single day, and the first row reaches its final state .. signed off by me personally, confirmed on my own phone.
|-
| 2026-06-11 || arbitrary precision becomes law for every input surface: no lumping, always splitting, always an Other with a fill-in-the-blank that actually stores. dead-end dropdowns are banned everywhere.
|-
| 2026-06-11 || I publish [https://artifacts.pharmacopedia.wiki/design/truisms/index.html a tribute to my father] on the public corpus page: 105 papers across five decades, gathered and made beautiful, in my own words, iterated word by word through the day.
|-
| .. || the record stays open.
|}

</div>

Methylphenidate

2026-06-16T06:46:26Z

MDElliottMD: B3 edit-4: Molina 2009 ref for MTA long-term claim (PMID 19318991); en-dash re-anchor; home-claude, mark-greenlit

{{MedTemplate
| generic = Methylphenidate
| brand = Ritalin, Ritalin LA, Concerta, Metadate CD, Daytrana, Quillivant XR
| structure = Methylphenidate.svg
| classes = Psychostimulant, NDRI
| mechanism = Norepinephrine–dopamine reuptake inhibition (DAT, NET)
| uses = ADHD, narcolepsy
| formula = C<sub>14</sub>H<sub>19</sub>NO<sub>2</sub>
| routes = Oral, transdermal
| onset = 20–60 min (oral)
| duration = IR 3–5 h; LA/SR 6–8 h; Concerta 10–12 h; Daytrana ~9 h wear time
| halflife = 2–3 h (parent compound)
| bioavailability = ~30% (high first-pass)
| pregnancy = Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion.
| legal = Schedule II
| intro = '''Methylphenidate''' is a piperidine-derivative central nervous system psychostimulant and the most widely prescribed med for attention-deficit hyperactivity disorder. First synthesized by Leandro Panizzon at Ciba in 1944 (and reportedly named "Ritalin" after his wife Rita, who used it), it has been clinically available since the mid-1950s. Mechanistically, methylphenidate is a pure norepinephrine–dopamine '''reuptake''' inhibitor, distinct from the amphetamines, which primarily ''release'' monoamines via reverse transport. This pharmacologic difference contributes to a somewhat smoother subjective profile and slightly lower abuse liability per milligram, though methylphenidate remains a Schedule II controlled substance with meaningful misuse potential. Multiple formulations exist (immediate-release, several extended-release oral preparations, a transdermal patch, and a chewable/liquid), allowing duration-of-action to be matched to clinical need. A 2018 systematic review and network meta-analysis by Cortese and colleagues identified methylphenidate as first-line pharmacotherapy for ADHD in children and adolescents (based on the balance of efficacy and tolerability), with amphetamines as first-line in adults.<ref name="cortese2018">Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2018;5(9):727–738.</ref>
| history =
Methylphenidate emerged from a chemistry program at the Swiss pharmaceutical company Ciba AG (later Ciba-Geigy, then Novartis) in the 1940s. Leandro Panizzon, a chemist at Ciba, synthesized the compound in 1944 while searching for a stimulant with a less abrupt and less euphoric profile than amphetamine. Panizzon and his colleagues observed the stimulant effect in animals and ultimately on themselves; the canonical anecdote, widely repeated in pharmacology histories and Ciba/Novartis corporate retrospectives, is that Panizzon's wife Marguerite ("Rita") used the compound as a mild stimulant before tennis matches, which inspired the trade name Ritalin.{{citation needed}}

Ciba launched methylphenidate as Ritalin in Switzerland in 1954 and in the United States the following year, originally marketed for narcolepsy, chronic fatigue, mild depression, senile behavioral problems, and as an amphetamine-overdose antidote (this last use long since abandoned). Clinical application to childhood behavioral disorders developed gradually through the late 1950s and 1960s; the diagnosis then was "minimal brain dysfunction" or "hyperkinetic reaction of childhood," the precursors to the modern attention-deficit hyperactivity disorder formulation.{{citation needed}}

Methylphenidate was placed on Schedule II of the U.S. Controlled Substances Act in 1971, alongside amphetamine and cocaine, where it has remained.<ref name="csa-1971">U.S. Drug Enforcement Administration. Controlled Substances Act (21 U.S.C. §§ 801–971), Schedule II. 21 CFR 1308.12.</ref> The 1990s and 2000s saw a marked expansion of ADHD diagnosis and methylphenidate prescribing in the United States, accompanied by the development of extended-release formulations (Concerta osmotic-pump tablets approved 2000; Ritalin LA 2002; Metadate CD 2001; Daytrana transdermal patch 2006) that reduced the practical burden of multiple-times-daily dosing and supported broader adult use.

The largest independent comparative-effectiveness data source on methylphenidate is the Multimodal Treatment of ADHD (MTA) study, a National Institute of Mental Health-funded randomized controlled trial published in 1999 that compared medication management (predominantly methylphenidate), behavioral therapy, the combination of both, and community standard care in 579 children aged 7–9 with ADHD. The medication and combined arms produced significantly greater improvement in ADHD symptoms than the behavioral or community arms at 14 months.<ref name="mta1999">MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry. 1999;56(12):1073–1086.</ref> Long-term follow-ups have moderated the short-term superiority finding, with diminishing between-group differences by 36 months and broadly comparable functional outcomes across arms by adulthood.<ref name="molina2009">Molina BSG, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 2009;48(5):484-500. PMID 19318991.</ref>

Cardiovascular safety in long-term outpatient use was characterized by Cooper and colleagues in a large 2011 cohort study published in the New England Journal of Medicine: among 1,200,438 children and young adults receiving ADHD medications, no significant association with serious cardiovascular events was found compared with non-users, after adjustment for cardiovascular risk factors.<ref name="cooper2011">Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. New England Journal of Medicine. 2011;365(20):1896–1904.</ref> A companion JAMA study by Habel and colleagues reached similar conclusions in adults.<ref name="habel2011">Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306(24):2673–2683.</ref> These analyses attenuated the post-2006 cardiac-safety concerns that had driven the peripheral vasculopathy and sudden-cardiac-death warnings, though the FDA warnings remain in place.
| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma levels in 1–2 hours for IR. Bioavailability is only ~30% due to extensive first-pass metabolism. Food modestly delays but does not significantly reduce absorption. The transdermal patch (Daytrana) bypasses first-pass and produces somewhat higher and steadier serum levels per dose. '''Distribution:''' Volume of distribution ~13 L/kg; plasma protein binding ~15%. Crosses the blood–brain barrier. '''Metabolism:''' Primarily metabolized by '''carboxylesterase 1 (CES1)''' in the liver, not by cytochrome P450 enzymes, to ritalinic acid, which is pharmacologically inactive. This metabolic route makes methylphenidate relatively free of CYP-mediated med interactions, distinguishing it from amphetamines. '''Stereochemistry:''' Methylphenidate has two stereocenters; the d-threo enantiomer carries essentially all pharmacologic activity. Dexmethylphenidate ([[Focalin]]) is the isolated d-threo enantiomer and is roughly twice as potent per milligram. '''Elimination:''' ~90% renally excreted as ritalinic acid; ~1% unchanged. Half-life of the parent compound is 2–3 hours, hence the need for extended-release formulations or multi-dose-daily schedules for sustained effect.<ref name="ritalin-label">U.S. Food and Drug Administration. Ritalin (methylphenidate hydrochloride) prescribing information. NDA 010187, Novartis Pharmaceuticals.</ref>
| pharmacodynamics = Methylphenidate binds to and competitively inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking reuptake of these monoamines from the synaptic cleft. Unlike amphetamines, methylphenidate is '''not a substrate''' for the transporters, it doesn't enter the presynaptic terminal, doesn't displace dopamine from vesicles, and doesn't induce reverse transport. The result is increased extracellular dopamine and norepinephrine without the additional vesicular release amphetamines produce.

Key effects:
* Affinity for DAT is roughly equal to or slightly greater than NET in binding studies, but functional consequences in prefrontal cortex are dominated by NET effects (because NET also clears dopamine in PFC).
* Minimal direct serotonergic activity at therapeutic doses.
* No meaningful MAO inhibition.
* No significant 5-HT, histamine, or muscarinic receptor binding.

The net therapeutic effect is enhanced catecholaminergic tone in prefrontal cortex (attention, executive function) and striatum (motor inhibition, reward processing), underlying both its therapeutic effects in ADHD and its abuse liability.
| indications = * Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults)
* Narcolepsy
* Off-label: treatment-resistant depression (augmentation, especially in geriatric or medically ill patients), fatigue in advanced illness (cancer, HIV, multiple sclerosis), excessive daytime sleepiness in shift-work disorder
| dosing = '''Ritalin IR (FDA-approved for children ≥6 y; adult use is common clinical practice but off-label for IR Ritalin specifically; several ER formulations carry adult ADHD indications):''' Start 5 mg PO twice daily (before breakfast and lunch); titrate by 5–10 mg/week. Max 60 mg/day in 2–3 divided doses.
'''Ritalin LA / Metadate CD:''' 20 mg PO once daily AM; titrate by 10–20 mg weekly. Max 60 mg/day.
'''Concerta (osmotic ER):''' Start 18 mg PO once daily AM. Titrate by 18 mg/week. Max 72 mg/day (adults); 54 mg/day (children).
'''Daytrana (transdermal patch):''' Apply 10 mg/9 h patch to alternating hip 2 h before effect needed; remove after 9 h. Titrate weekly to max 30 mg/9 h.
'''Focalin (d-methylphenidate):''' Use half the equivalent racemic dose.
'''Narcolepsy:''' 10–60 mg/day in divided doses.
'''Renal/hepatic impairment:''' caution; no specific adjustment guidelines but reduce dose and monitor.
| effects = ''Therapeutic:'' improved attention, reduced impulsivity and hyperactivity, increased wakefulness, mild mood elevation, mild appetite suppression. Generally described as "smoother" and less euphoric than amphetamines at equivalent doses.
''Common adverse:'' decreased appetite, insomnia (especially with late dosing), headache, abdominal pain, mild irritability, dry mouth, mild elevation of heart rate and blood pressure, weight loss.
| adverse = * '''Cardiovascular:''' tachycardia, mild–moderate hypertension; rare reports of sudden cardiac death in patients with structural heart disease.<ref name="fda-mph-cv-2007">U.S. Food and Drug Administration. FDA Directs ADHD Drug Manufacturers to Notify Patients about Cardiovascular Adverse Events and Psychiatric Adverse Events. February 21, 2007.</ref><ref name="vetter2008">Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: a scientific statement from the American Heart Association. Circulation. 2008;117(18):2407–2423.</ref>
* '''Psychiatric:''' anxiety, agitation, irritability, mood lability; rarely psychosis or mania (especially in patients with bipolar predisposition)
* '''Tics''', methylphenidate can unmask or worsen motor/vocal tics; comorbid Tourette syndrome is a traditional but increasingly contested relative contraindication
* '''Dependence and misuse''', Schedule II; oral therapeutic use has lower abuse liability than amphetamines, but crushed/insufflated/IV misuse is significant
* '''Growth suppression''', modest reduction in height/weight velocity in chronically-treated children
* '''Priapism''', rare but documented; FDA warning, especially in adolescents.<ref name="fda-mph-priapism-2013">U.S. Food and Drug Administration. FDA Drug Safety Communication: Safety review update of medical drugs used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults. December 17, 2013 (priapism class warning).</ref>
* '''Peripheral vasculopathy''', Raynaud-like phenomenon, rare digital ischemia.<ref name="fda-mph-vasculopathy-2006">U.S. Food and Drug Administration. FDA Drug Safety Communication: peripheral vasculopathy including Raynaud phenomenon associated with stimulants used to treat ADHD. December 2006.</ref>
* '''Lowered seizure threshold''', caution in epilepsy
* '''Lassitude / "crash"''' on withdrawal, fatigue, dysphoria, rebound hyperactivity
* '''Stereotyped behaviors''', rare at therapeutic doses
* '''Skin reactions''', chemical leukoderma (permanent depigmentation) at Daytrana patch application sites.<ref name="fda-daytrana-leukoderma-2015">U.S. Food and Drug Administration. FDA Drug Safety Communication: Permanent skin color loss (chemical leukoderma) reported with use of Daytrana patch (methylphenidate transdermal system). June 24, 2015.</ref>
| interactions = * '''MAOIs''' (phenelzine, tranylcypromine, selegiline, linezolid), hypertensive crisis risk; contraindicated
* '''Tricyclic antidepressants''', additive sympathomimetic cardiovascular effects (tachycardia, hypertension). Older case reports suggested possible PK interaction elevating TCA levels; modern reviews do not support a clinically significant PK interaction as methylphenidate does not appreciably inhibit CYP2D6.
* '''Warfarin / coumarins''', methylphenidate may elevate INR
* '''Phenytoin, phenobarbital, primidone''', methylphenidate may elevate anticonvulsant levels
* '''Antihypertensives''', methylphenidate's pressor effect may partially antagonize
* '''Other sympathomimetics''' (pseudoephedrine, phenylephrine, decongestants), additive cardiovascular effects
* '''Neuroleptics''', pharmacologic antagonism (each may partially block the other's effects)
* '''Alcohol''', may mask intoxication; may release more d-methylphenidate from racemic preparations via stereoselective metabolism
* '''Caffeine''', additive psychostimulant and anxiogenic effects

Notably, '''few CYP-mediated interactions''' because methylphenidate is metabolized by CES1, not P450s, a clinical advantage over amphetamine when polypharmacy is a concern.
<pharmaInteractions/>
| pregnancy_details = Crosses the placenta. Less reproductive data than amphetamine; available evidence does not show a clear pattern of major teratogenicity, but cohort studies suggest small increases in cardiac malformations and other anomalies, interpretation complicated by confounding by problem. Third-trimester exposure can produce transient neonatal withdrawal (irritability, feeding difficulty). Generally a risk-benefit decision; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in small amounts; breastfeeding generally compatible at therapeutic doses with infant monitoring.
| monitoring = * Baseline: cardiovascular history (including family history of sudden cardiac death), blood pressure, heart rate, weight/height, mental health history, history of tics or substance use
* Consider ECG if cardiac risk factors are present
* At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence
* Periodically reassess continued need; consider med holidays in children to assess ongoing benefit and minimize growth-velocity effects
* Sleep quality and timing of last dose
| counseling = * Take in the morning; avoid afternoon dosing to minimize insomnia.
* '''Do not crush, chew, or split extended-release tablets/capsules.'''
* '''Concerta:''' the osmotic tablet shell will appear intact in stool, this is normal and does not mean the med wasn't absorbed.
* Eat regular meals despite appetite suppression; weigh periodically.
* Stay well-hydrated.
* Do not combine with significant alcohol or other psychostimulants.
* Do not share or sell, Schedule II controlled substance; serious legal and clinical consequences.
* Report chest pain, palpitations, severe agitation, hallucinations, prolonged erection, or new/worsening tics.
* Skin patches: rotate site daily to avoid persistent depigmentation; remove after 9 hours.
* Plan for the "crash" when the dose wears off, particularly with IR formulations late afternoon.
* If discontinuing after long use, expect a few days of fatigue and possible dysphoria.
| anecdotes =
<anecdote slug="2026-05-14" perspective="provider" author="MDElliottMD">
Rumor has it that it can be more effective during the luteal phase of the menstrual cycle. Anyone have experience?
</anecdote>
| seealso = [[Mixed amphetamine salts]], [[Dextroamphetamine]], [[Dexmethylphenidate]], [[Lisdexamfetamine]], [[Modafinil]], [[Atomoxetine]], [[Viloxazine]]
| references = <references/>
}}

[[Category:Psychostimulants]]
[[Category:Methylphenidates (Phenidates)]]

Acetaminophen

2026-06-15T07:34:06Z

MDElliottMD: Acetaminophen safety depth (launch gate): Overdose+toxicity (Rumack-Matthew nomogram, NAC regimens) + Combination products/325mg FDA cap sections; template byte-preserved; multi-review-passed + mark-greenlit

{{MedTemplate
| generic = Acetaminophen (paracetamol, APAP)
| brand = Tylenol, Panadol (international), Ofirmev (IV); huge OTC presence
| structure =
| classes = [[:Category:Analgesics|Non-opioid analgesic]], [[:Category:Antipyretics|Antipyretic]]
| uses = <vote slug="mild-moderate-pain-use">Mild to moderate pain</vote>, <vote slug="fever-use">Fever</vote>, <vote slug="multimodal-analgesia-use">Multimodal post-surgical analgesia</vote>
| starting_dose = 325-1000 mg PO every 4-6 hours as needed; maximum 4 g/d in healthy adults, 3 g/d in regular users or hepatic risk; pediatric 10-15 mg/kg every 4-6 hours
| preparations = 325, 500, 650 mg tablets; 80, 160 mg chewables; 160 mg/5 mL pediatric liquid; 325 mg suppository; 1000 mg/100 mL IV (Ofirmev); fixed-dose combinations with opioids, decongestants, antihistamines
| fda_max = 4 g/d in healthy adults; 3 g/d conservative limit; 2 g/d in cirrhosis or chronic alcohol use
| pill_id =
| routes = Oral, rectal, IV
| onset = PO: 30-60 minutes; IV: minutes
| duration = 4-6 hours
| halflife = 1-3 hours (normal liver); markedly prolonged in overdose with glutathione depletion<ref name="tylenol-label">FDA OTC Monograph for acetaminophen-containing products, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021450s015lbl.pdf</ref>
| bioavailability = ~85-98% (oral)<ref name="tylenol-label" />
| pregnancy = Long the preferred analgesic-antipyretic in pregnancy; recent observational studies have raised speculative neurodevelopmental signals that remain under investigation.{{citation needed}}
| legal = OTC and [[USLegal:Prescription only|Rx-only]] (IV, combination products) in US
| mechanism = <vote slug="apap-mech-claim">Acetaminophen's analgesic and antipyretic actions are incompletely characterized; central COX inhibition (particularly the COX-2 splice variant sometimes called COX-3, and inhibition of arachidonic acid pathways in CNS at low peroxide concentrations) is the leading hypothesis, with possible contribution from descending serotonergic pathways and TRPV1 modulation by the AM404 metabolite.</vote> The absence of meaningful peripheral cyclooxygenase inhibition explains the lack of antiplatelet and anti-inflammatory effect compared with NSAIDs, and the gastroprotective profile. '''Dose-dependent hepatotoxicity''' via the CYP2E1 metabolite N-acetyl-p-benzoquinone imine (NAPQI) once glutathione is depleted; N-acetylcysteine is the antidote and is most effective within 8-10 hours of overdose<ref name="tylenol-label" />.
}}

== Overdose and toxicity ==
For a single acute ingestion at a known time, the Rumack-Matthew nomogram guides
whether to treat: a serum acetaminophen concentration is drawn no earlier than 4 hours
after ingestion and plotted against time.<ref>Rumack BH, Matthew H. Acetaminophen
poisoning and toxicity. Pediatrics. 1975;55(6):871-876.</ref> In the United States the
treatment line begins at 150 micrograms/mL at 4 hours (set 25% below Rumack and Matthew's
original 200 micrograms/mL line, the FDA-adopted treatment threshold); a level on or above the line
indicates N-acetylcysteine, a level below it does not.<ref>Wallace CI, Dargan PI, Jones
AL. Paracetamol overdose: an evidence based flowchart to guide management. Emerg Med J.
2002;19(3):202-205.</ref> The nomogram does NOT apply to chronic or repeated
(staggered) ingestion, an unknown ingestion time, levels drawn before 4 hours, or
modified/extended-release products; in those situations N-acetylcysteine is given
empirically with serial transaminase and acetaminophen monitoring.

Two established N-acetylcysteine regimens are used. The intravenous 21-hour (Prescott)
regimen gives 150 mg/kg as a loading dose, then 50 mg/kg over the next 4 hours, then
100 mg/kg over the following 16 hours.<ref>Prescott LF, Illingworth RN, Critchley JA, et
al. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. Br
Med J. 1979;2(6198):1097-1100.</ref> The oral 72-hour regimen gives a 140 mg/kg loading
dose, then 70 mg/kg every 4 hours for 17 doses.<ref>Smilkstein MJ, Knapp GL, Kulig KW,
Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose.
N Engl J Med. 1988;319(24):1557-1562.</ref> Treatment is most effective when started
within 8 hours of ingestion, but is still given later, and in established liver injury or
acute liver failure, where it improves outcomes. Massive or late-presenting overdose may
require extended or increased dosing. This is reference information, not a treatment
protocol; overdose is a medical emergency managed by clinicians and poison control.

== Combination products and the 325 mg limit ==
Because acetaminophen is present in many products at once -- prescription opioid
combinations (e.g. hydrocodone/acetaminophen, oxycodone/acetaminophen) and over-the-
counter cold, flu, and sleep products -- people can exceed the maximum daily dose without
realizing it by stacking several acetaminophen-containing products, a leading route to
unintentional hepatotoxicity. In January 2011 the FDA acted on this risk for PRESCRIPTION
acetaminophen products: it asked manufacturers to limit acetaminophen to 325 mg per dosage
unit in prescription combination products (a change manufacturers completed by 2014), and it
required a boxed warning on all prescription products containing acetaminophen highlighting
the potential for severe liver injury.<ref>U.S. Food and Drug Administration. Drug Safety
Communication: Prescription acetaminophen products to be limited to 325 mg per dosage unit;
boxed warning will highlight potential for severe liver failure. January 13, 2011.</ref>
Over-the-counter acetaminophen products instead carry a Drug Facts "Liver warning," not a
boxed warning. Checking every product label for acetaminophen (sometimes abbreviated APAP)
and summing the total is the practical safeguard.

== References ==
<references />
[[Category:Analgesics]]
[[Category:Antipyretics]]

Template:MedTemplate

2026-06-14T21:33:10Z

MDElliottMD: Launch Gate 2: per-medicine disclaimer band (mark-approved)

<includeonly><div class="medpage"><div class="titleblock"><div class="tb-eyebrow">{{{classes|}}}</div><div class="tb-row"><div class="tb-name">{{{generic|{{PAGENAME}}}}}</div>{{#if:{{{brand|}}}|<div class="tb-brand">{{{brand}}}</div>}}</div></div>{{#cargo_store:_table=Medicines
| generic={{{generic|}}}
| brand={{{brand|}}}
| structure={{{structure|}}}
| classes={{{classes|}}}
| mechanism={{{mechanism|}}}
| uses={{{uses|}}}
| starting_dose={{{starting_dose|}}}
| preparations={{{preparations|}}}
| fda_max={{{fda_max|}}}
| pill_id={{{pill_id|}}}
| routes={{{routes|}}}
| onset={{{onset|}}}
| duration={{{duration|}}}
| halflife={{{halflife|}}}
| bioavailability={{{bioavailability|}}}
| pregnancy={{{pregnancy|}}}
| legal={{{legal|}}}
}}<div class="med-grid"><div class="med-main">{{#if:{{{intro|}}}|
{{{intro}}}
}}{{#if:{{{history|}}}|<div class="med-sec-head"><h2 class="sec-title" id="History">History</h2></div>
{{{history}}}}}<div class="med-sec-head"><h2 class="sec-title" id="Experience">Experience</h2></div>
<pharmaExperience/>
<div class="med-sec-head"><h2 class="sec-title" id="Problems">Problems</h2></div>
{{#if:{{{indications|}}}|{{{indications}}}|<p style="opacity:0.7; font-style:italic;">No problems yet. Be the first to suggest one.</p>}}

<span class="pcp-problem-suggest-wrap">[[Special:SuggestProblem/{{FULLPAGENAME}}|+ Add a problem]]</span><div class="med-sec-head"><h2 class="sec-title" id="Titration">Titration strategies</h2></div>
{{#if:{{{dosing|}}}|{{{dosing}}}|<p style="opacity:0.7; font-style:italic;">No titration strategies yet. Be the first to suggest one.</p>}}

<span class="pcp-titration-suggest-wrap">[[Special:SuggestTitration/{{FULLPAGENAME}}|+ Add a titration strategy]]</span>

<div class="med-sec-head"><h2 class="sec-title" id="Effects">Effects</h2></div>
{{#if:{{{effects|}}}{{{adverse|}}}|{{{effects|}}}{{#if:{{{adverse|}}}|

{{{adverse}}}}}|<p style="opacity:0.7; font-style:italic;">No effects listed yet. Be the first to suggest one.</p>}}

<span class="pcp-effect-suggest-wrap">[[Special:SuggestEffect/{{FULLPAGENAME}}|+ Add an effect]]</span>
{{#if:{{{pharmacokinetics|}}}{{{pk_absorption|}}}{{{pk_distribution|}}}{{{pk_metabolism|}}}{{{pk_elimination|}}}|<div class="med-sec-head"><h2 class="sec-title" id="Pharmacokinetics">Pharmacokinetics</h2></div>
{{#if:{{{pk_absorption|}}}|<h3 class="med-subhead" id="Absorption">Absorption</h3>
{{{pk_absorption}}}
}}{{#if:{{{pk_distribution|}}}|<h3 class="med-subhead" id="Distribution">Distribution</h3>
{{{pk_distribution}}}
}}{{#if:{{{pk_metabolism|}}}|<h3 class="med-subhead" id="Metabolism">Metabolism</h3>
{{{pk_metabolism}}}
}}{{#if:{{{pk_elimination|}}}|<h3 class="med-subhead" id="Elimination">Elimination</h3>
{{{pk_elimination}}}
}}{{#if:{{{pharmacokinetics|}}}|
{{{pharmacokinetics}}}}}
}}{{#if:{{{pharmacodynamics|}}}|<div class="med-sec-head"><h2 class="sec-title" id="Pharmacodynamics">Pharmacodynamics</h2></div>
{{{pharmacodynamics}}}}}{{#if:{{{interactions|}}}|<div class="med-sec-head"><h2 class="sec-title" id="Interactions">Interactions</h2></div>
{{{interactions}}}}}{{#if:{{{pregnancy_details|}}}|<div class="med-sec-head"><h2 class="sec-title" id="Pregnancy">Pregnancy and lactation</h2></div>
{{{pregnancy_details}}}}}{{#if:{{{monitoring|}}}|<div class="med-sec-head"><h2 class="sec-title" id="Monitoring">Monitoring</h2></div>
{{{monitoring}}}}}{{#if:{{{counseling|}}}|<div class="med-sec-head"><h2 class="sec-title" id="Counseling">Patient counseling</h2></div>
{{{counseling}}}}}<div class="med-sec-head"><h2 class="sec-title" id="Anecdote">Relevant anecdote</h2></div>
{{#if:{{{anecdotes|}}}|{{{anecdotes}}}|<p style="opacity:0.7; font-style:italic;">No anecdotes yet. Share a relevant one.</p>}}

<span class="pcp-anecdote-suggest-wrap">[[Special:SuggestAnecdote/{{FULLPAGENAME}}|+ Add an anecdote]]</span>
<div class="med-sec-head"><h2 class="sec-title" id="Literature">Relevant Literature</h2></div>
<pharmaLiterature/>
{{#if:{{{seealso|}}}|<div class="med-sec-head"><h2 class="sec-title" id="SeeAlso">See also</h2></div>
{{{seealso}}}}}{{#if:{{{references|}}}|<div class="med-sec-head"><h2 class="sec-title" id="References">References</h2></div>
{{{references}}}}}</div><div class="med-rail"><div class="med-rail-inner"><div class="med-channel ch-pharmacy"><div class="ch-head"><span class="ch-mark"></span><span class="ch-name">Pharmacy</span></div>{{#if:{{{starting_dose|}}}|<div class="med-field"><div class="fl">Starting dose</div><div class="fv">{{{starting_dose}}}</div></div>}}{{#if:{{{preparations|}}}|<div class="med-field"><div class="fl">Preparations</div><div class="fv">{{{preparations}}}</div></div>}}{{#if:{{{fda_max|}}}|<div class="med-field"><div class="fl">US FDA Max</div><div class="fv">{{{fda_max}}}</div></div>}}{{#if:{{{pill_id|}}}|<div class="med-field"><div class="fl">Pill ID</div><div class="fv"><div class="pcp-pill-id"><div class="mw-collapsible mw-collapsed" data-expandtext="Show pill identifiers" data-collapsetext="Hide pill identifiers">
{{{pill_id}}}
</div></div></div></div>}}</div><div class="med-channel ch-uses"><div class="ch-head"><span class="ch-mark"></span><span class="ch-name">Common uses</span></div><pharmaCommonUses>{{{uses|}}}</pharmaCommonUses></div>{{#if:{{{structure|}}}|<div class="med-channel ch-structure"><div class="ch-head"><span class="ch-mark"></span><span class="ch-name">Structure</span></div><div class="med-structure">[[File:{{{structure}}}|frameless|{{{structuresize|240px}}}|alt=Structure of {{{generic|{{PAGENAME}}}}}]]</div></div>}}<div class="med-channel ch-classes"><div class="ch-head"><span class="ch-mark"></span><span class="ch-name">Classification(s)</span></div>{{#if:{{{classes|}}}|<div class="med-field"><div class="fl">Classes</div><div class="fv">{{{classes}}}</div></div>}}</div><div class="med-channel ch-pharmacology"><div class="ch-head"><span class="ch-mark"></span><span class="ch-name">Pharmacology</span></div>{{#if:{{{routes|}}}|<div class="med-field"><div class="fl">Routes</div><div class="fv">{{{routes}}}</div></div>}}{{#if:{{{onset|}}}|<div class="med-field"><div class="fl">Onset</div><div class="fv">{{{onset}}}</div></div>}}{{#if:{{{duration|}}}|<div class="med-field"><div class="fl">Duration</div><div class="fv">{{{duration}}}</div></div>}}{{#if:{{{halflife|}}}|<div class="med-field"><div class="fl">Half-life</div><div class="fv">{{{halflife}}}</div></div>}}{{#if:{{{bioavailability|}}}|<div class="med-field"><div class="fl">Bioavailability</div><div class="fv">{{{bioavailability}}}</div></div>}}{{#if:{{{pregnancy|}}}|<div class="med-field"><div class="fl">Pregnancy</div><div class="fv">{{{pregnancy}}}</div></div>}}{{#if:{{{legal|}}}|<div class="med-field"><div class="fl">Legal status</div><div class="fv">{{{legal}}}</div></div>}}{{#if:{{{mechanism|}}}|<div class="med-field"><div class="fl">Purported mechanism</div><div class="fv">{{{mechanism}}}</div></div>}}</div></div></div></div><div class="med-disclaimer">Pharmacopedia is intended for reference. Nothing here is advice. In an emergency call 911; US Poison Control 1-800-222-1222. See the [[Pharmacopedia:General disclaimer|full disclaimer]].</div>[[Category:Medicines]]</div></includeonly><noinclude>
{{#cargo_declare:_table=Medicines
| generic=String
| brand=String
| structure=File
| classes=List (,) of String
| mechanism=String
| uses=String
| starting_dose=String
| preparations=String
| fda_max=String
| pill_id=Text
| routes=List (,) of String
| onset=String
| duration=String
| halflife=String
| bioavailability=String
| pregnancy=String
| legal=String
}}

== Usage ==

Medicine entry template. Fill in fields below; empty fields are auto-omitted.

The <code>problems</code> parameter still uses the historical name in template wikitext to preserve compatibility with every existing medicine page; the rendered H2 heading on the page now reads "Problems" (see [[Special:Problems]] for the repository and [[Pharmacopedia:Citation needed]] adjacent context).

<pre>
{{MedTemplate
| generic =
| brand =
| structure =
| classes =
| uses =
| starting_dose =
| preparations =
| fda_max =
| pill_id =
| routes =
| onset =
| duration =
| halflife =
| bioavailability =
| pregnancy =
| legal =
| mechanism =
| intro =
| history =
| indications =
| dosing =
| effects =
| pk_absorption =
| pk_distribution =
| pk_metabolism =
| pk_elimination =
| pharmacodynamics =
| interactions =
| pregnancy_details =
| monitoring =
| counseling =
| anecdotes =
| seealso =
| references =
}}
</pre>

Notes:
* ''The'' <code>problems</code> ''parameter feeds the "Problems" H2 section on the rendered page. Content typically consists of'' <code><problem ref="..."/></code> ''tags (formerly'' <code><problem ref="..."/></code>'').'' ''Use'' <code>[[Special:SuggestProblem|SuggestProblem]]</code> ''or the per-page'' <code>+ Add a problem</code> ''link to propose new entries.''
* ''The'' <code>adverse</code> ''parameter is deprecated; its content is still rendered, but new pages should combine therapeutic and adverse effects into the single'' <code>effects</code> ''parameter.''
* ''The'' <code>formula</code> ''parameter is deprecated and no longer rendered. It can be removed from existing pages.''
* ''The single'' <code>pharmacokinetics</code> ''parameter is deprecated; new pages should use'' <code>pk_absorption</code>'','' <code>pk_distribution</code>'','' <code>pk_metabolism</code>'', and'' <code>pk_elimination</code>''.''

This template also populates the '''Medicines''' Cargo table. See [[Special:CargoTables/Medicines]].

[[Category:Templates]]
</noinclude>

Pharmacopedia:General disclaimer

2026-06-14T21:32:24Z

MDElliottMD: Launch Gate 2: medical disclaimer page (fixes footer 404; mark-approved)

__NOTOC__
'''Pharmacopedia is intended for reference. Nothing here is advice.'''

If you're looking for advice, please speak to a clinician directly. Nothing here can replace a clinician's expertise. If you have a medical question or emergency, consult a licensed clinician or call emergency services. For overdose or poisoning in the United States, call Poison Control at 1-800-222-1222.

This disclaimer applies to every page on Pharmacopedia.

Warfarin

2026-06-13T18:04:49Z

MDElliottMD: B3 citation patch (home-claude, PM-approved): clear [citation needed] with verified ref

{{MedTemplate
| generic = Warfarin
| brand = Coumadin (discontinued in US but name in common use), Jantoven
| structure =
| classes = [[:Category:Anticoagulants|Anticoagulant]], [[:Category:Vitamin_K_antagonists|Vitamin K antagonist]]
| uses = <vote slug="mechanical-heart-valve-use">Mechanical heart valves</vote>, <vote slug="aps-use">Antiphospholipid syndrome thromboprophylaxis</vote>, <vote slug="aaf-stroke-prevention-valve-use">Atrial fibrillation with mitral stenosis or mechanical valves</vote>, <vote slug="vte-treatment-use">VTE treatment and secondary prevention</vote>, <vote slug="ckd5-vte-use">VTE in advanced CKD (DOACs less established)</vote>
| starting_dose = Typical 5 mg PO daily; 2.5 mg in elderly, low body weight, malnutrition, hepatic dysfunction. Genotype-guided initial dosing per CPIC/IWPC algorithms (CYP2C9, VKORC1, CYP4F2) is one of the most-established PGx applications in current practice
| preparations = 1, 2, 2.5, 3, 4, 5, 6, 7.5, 10 mg tablets (color-coded by strength)
| fda_max = No fixed maximum; titrated to INR target
| pill_id =
| routes = Oral, IV (rarely used; same dose)
| onset = Anticoagulant effect at 24-72 hours; full INR effect 5-7 days
| duration = 2-5 days after stopping (factor II resynthesis-limited)
| halflife = 36-42 hours (R/S enantiomers differ; S-warfarin is 2-5× more potent and cleared by CYP2C9)<ref name="coumadin-label">FDA Prescribing Information, Coumadin (warfarin sodium), Bristol-Myers Squibb, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009218s108lbl.pdf</ref>
| bioavailability = ~100% (oral)<ref name="coumadin-label" />
| pregnancy = '''Contraindicated in pregnancy''' (warfarin embryopathy, fetal hemorrhage) except in mechanical mitral valves where the maternal mortality of alternative agents may exceed fetal risk.<ref name="coumadin-label" />
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="warfarin-mech-claim">Warfarin inhibits vitamin K epoxide reductase complex 1 (VKORC1), preventing regeneration of reduced vitamin K and γ-carboxylation of glutamate residues on factors II, VII, IX, X, and proteins C and S; the result is hypofunctional clotting factors, the most clinically important being factor II (prothrombin, half-life ~60 hours) whose depletion drives the steady-state anticoagulant effect.</vote> CYP2C9 (S-warfarin clearance) and VKORC1 (drug target) polymorphisms together explain 30-50% of inter-individual dosing variance and are the prototype pharmacogenomic target in clinical use<ref name="cpic-warfarin">CPIC Guideline for CYP2C9, VKORC1, CYP4F2, and Warfarin, 2017. https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/</ref>. Reversal: vitamin K, 4F-PCC for life-threatening bleeding (FFP if PCC unavailable).
}}

== References ==
<references />
[[Category:Anticoagulants]]
[[Category:Vitamin K antagonists]]

Desiccated thyroid

2026-06-13T18:04:47Z

MDElliottMD: B3 citation patch (home-claude, PM-approved): clear [citation needed] with verified ref

Desiccated thyroid (also called natural thyroid, thyroid extract, or by the historical brand Armour Thyroid) is porcine thyroid gland, defatted and powdered, containing both thyroxine (T4) and triiodothyronine (T3) in a fixed ratio of roughly 4:1 by weight as required by the United States Pharmacopeia<ref name="armour-label">FDA Prescribing Information, Armour Thyroid (thyroid tablets, USP), Allergan, current revision. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=003444</ref>. It was introduced in 1892 by George Murray and has been continuously prescribed since, predating both the isolation of thyroxine (1914) and the synthetic levothyroxine of the 1950s. Modern endocrinology guidelines prefer synthetic [[Levothyroxine]] as first-line replacement, but a residual population of patients and clinicians prefer desiccated thyroid for its T3 content and historical track record.

{{MedTemplate
| generic = Thyroid (desiccated)
| brand = Armour Thyroid, NP Thyroid, Nature-Throid, WP Thyroid
| structure =
| classes = [[:Category:Thyroid_hormones|Thyroid hormone]], [[:Category:Hormone_replacement|Hormone replacement]]
| uses = <vote slug="hypothyroidism-use">Hypothyroidism</vote>, <vote slug="goiter-use">Goiter</vote>
| starting_dose = 30 mg PO daily (1/2 grain); titrate by TSH at 6-8 weeks; 60 mg desiccated thyroid is approximately equivalent to 88-100 mcg levothyroxine
| preparations = 15, 30, 60, 90, 120, 180, 240, 300 mg tablets (1/4 to 5 grains; 1 grain = 60 mg)
| fda_max = No fixed maximum; titrated to TSH target
| pill_id =
| routes = Oral
| onset = TSH normalization 4-8 weeks
| duration = Steady-state at 4-6 weeks
| halflife = T4 ~7 days; T3 ~1 day<ref name="armour-label" />
| bioavailability = Variable; reduced by food, calcium, iron, PPIs<ref name="armour-label" />
| pregnancy = Synthetic levothyroxine is the standard-of-care in pregnancy; desiccated thyroid use in pregnancy is not well studied.<ref name="ata2017-preg">Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315-389. PMID 28056690.</ref>
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="desiccated-thyroid-mech-claim">Desiccated thyroid supplies both T4 and T3 in a roughly 4:1 ratio; T4 is peripherally deiodinated to T3, but exogenous T3 supplementation produces faster onset and supraphysiologic post-dose peaks that synthetic T4 monotherapy avoids.</vote> Brand-to-brand and lot-to-lot variability in T3:T4 ratio is greater than with synthetic levothyroxine, which is why endocrine guidelines prefer the synthetic<ref name="armour-label" />.
}}

== References ==
<references />

Liothyronine

2026-06-13T18:04:45Z

MDElliottMD: B3 citation patch (home-claude, PM-approved): clear [citation needed] with verified ref

{{MedTemplate
| generic = Liothyronine (T3, triiodothyronine sodium)
| brand = Cytomel (oral), Triostat (IV)
| structure =
| classes = [[:Category:Thyroid_hormones|Thyroid hormone]], [[:Category:Hormone_replacement|Hormone replacement]]
| uses = <vote slug="hypothyroidism-T3-adjunct-use">Hypothyroidism (T3 supplement, selected refractory cases)</vote>, <vote slug="myxedema-coma-use">Myxedema coma (IV, in addition to T4)</vote>, <vote slug="thyroid-cancer-tsh-suppression-bridge-use">Bridge between T4 withdrawal and radioiodine scan/treatment in thyroid cancer</vote>
| starting_dose = Hypothyroidism: 5-25 mcg PO daily (start low, titrate slowly); myxedema coma: 5-20 mcg IV q4-12h with T4 loading
| preparations = 5, 25, 50 mcg tablets (Cytomel); 10 mcg/mL IV (Triostat)
| fda_max = 100 mcg/d typical
| pill_id =
| routes = Oral, IV
| onset = Hours (faster than T4); peak biologic activity 24-48 hours
| duration = 24-72 hours
| halflife = ~1 day (much shorter than T4's ~7 days)<ref name="cytomel-label">FDA Prescribing Information, Cytomel (liothyronine sodium), Pfizer/King, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/010379s055lbl.pdf</ref>
| bioavailability = ~95% (oral)<ref name="cytomel-label" />
| pregnancy = T4 (levothyroxine) is the first-line in pregnancy; T3 is rarely needed.<ref name="ata2017-preg">Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315-389. PMID 28056690.</ref>
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="liothyronine-mech-claim">Liothyronine is bioidentical T3 (triiodothyronine), the active thyroid hormone that binds nuclear thyroid hormone receptors with ~10× the affinity of T4; T4 (levothyroxine) is essentially a prodrug peripherally deiodinated to T3.</vote> Direct T3 supplementation bypasses peripheral deiodination, useful in myxedema coma (rapid clinical effect needed) and in some refractory hypothyroidism (combination T4+T3, controversial). Short half-life produces fluctuating serum levels with intermittent supraphysiologic peaks — one reason T4 monotherapy remains the practical standard<ref name="cytomel-label" />.
}}

== References ==
<references />
[[Category:Thyroid hormones]]
[[Category:Hormone replacement]]

Problem:Weight loss

2026-06-13T06:05:32Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Intentional weight reduction (overlaps with obesity but covers users without that diagnosis).

== Medicines used for Weight loss ==

<problemMedicines slug="weight-loss" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Vomiting

2026-06-13T06:05:30Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Forceful expulsion of gastric contents.

== Medicines used for Vomiting ==

<problemMedicines slug="vomiting" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Vertigo

2026-06-13T06:05:28Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Illusory sensation of self or environmental motion.

== Medicines used for Vertigo ==

<problemMedicines slug="vertigo" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:VTE prevention or treatment

2026-06-13T06:05:27Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Prevention or treatment of venous thromboembolism (DVT/PE).

== Medicines used for VTE prevention or treatment ==

<problemMedicines slug="anticoagulation-vte" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Type 2 diabetes mellitus

2026-06-13T06:05:25Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Diabetes mellitus, type 2 — insulin resistance with relative insulin deficiency.

== Medicines used for Type 2 diabetes mellitus ==

<problemMedicines slug="diabetes-type-2" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Type 2 Diabetes Mellitus

2026-06-13T06:05:23Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Type 2 Diabetes Mellitus ==

<problemMedicines slug="type-2-diabetes-mellitus" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Type 1 Diabetes Mellitus

2026-06-13T06:05:21Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Type 1 Diabetes Mellitus ==

<problemMedicines slug="type-1-diabetes-mellitus" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Trichotillomania

2026-06-13T06:05:19Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Trichotillomania ==

<problemMedicines slug="trichotillomania" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Treatment-resistant depression (augmentation)

2026-06-13T06:05:17Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Treatment-resistant depression (augmentation) ==

<problemMedicines slug="trd-augment" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Treatment-Resistant Depression

2026-06-13T06:05:16Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

A major depressive episode that has not responded adequately to two or more adequate trials of antidepressant medicines.

== Medicines used for Treatment-Resistant Depression ==

<problemMedicines slug="treatment-resistant-depression" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Traumatic Brain Injury

2026-06-13T06:05:13Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Traumatic Brain Injury ==

<problemMedicines slug="traumatic-brain-injury" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Tourette Syndrome

2026-06-13T06:05:12Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Tourette Syndrome ==

<problemMedicines slug="tourette-syndrome" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Tobacco Use Disorder

2026-06-13T06:05:10Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

A problematic pattern of tobacco use leading to clinically significant impairment or distress.

== Medicines used for Tobacco Use Disorder ==

<problemMedicines slug="tobacco-use-disorder" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Tension-type headache

2026-06-13T06:05:08Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Bilateral pressing/tightening headache, mild–moderate intensity.

== Medicines used for Tension-type headache ==

<problemMedicines slug="tension-headache" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Stimulant Use Disorder

2026-06-13T06:05:06Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Stimulant Use Disorder ==

<problemMedicines slug="stimulant-use-disorder" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Specific Learning Disorder with Dyslexia

2026-06-13T06:05:04Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Specific Learning Disorder with Dyslexia ==

<problemMedicines slug="specific-learning-disorder-with-dyslexia" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Specific Learning Disorder with Dyscalculia

2026-06-13T06:05:02Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Specific Learning Disorder with Dyscalculia ==

<problemMedicines slug="specific-learning-disorder-with-dyscalculia" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Social anxiety disorder

2026-06-13T06:05:01Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Social anxiety disorder ==

<problemMedicines slug="social-anxiety" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Social Anxiety Disorder

2026-06-13T06:04:59Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Social Anxiety Disorder ==

<problemMedicines slug="social-anxiety-disorder" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Smoking cessation

2026-06-13T06:04:57Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Tobacco/nicotine cessation pharmacotherapy.

== Medicines used for Smoking cessation ==

<problemMedicines slug="smoking-cessation" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Sensory Processing Sensitivity

2026-06-13T06:04:55Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Sensory Processing Sensitivity ==

<problemMedicines slug="sensory-processing-sensitivity" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Sensory Processing Disorder

2026-06-13T06:04:53Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Sensory Processing Disorder ==

<problemMedicines slug="sensory-processing-disorder" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Seasonal Affective Disorder

2026-06-13T06:04:52Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Seasonal Affective Disorder ==

<problemMedicines slug="seasonal-affective-disorder" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Schizotypal Personality Disorder

2026-06-13T06:04:50Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Schizotypal Personality Disorder ==

<problemMedicines slug="schizotypal-personality-disorder" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Schizophrenia

2026-06-13T06:04:49Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Schizophrenia ==

<problemMedicines slug="schizophrenia" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Schizoid Personality Disorder

2026-06-13T06:04:47Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Schizoid Personality Disorder ==

<problemMedicines slug="schizoid-personality-disorder" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Schizoaffective Disorder

2026-06-13T06:04:46Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Schizoaffective Disorder ==

<problemMedicines slug="schizoaffective-disorder" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Rosacea

2026-06-13T06:04:44Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Chronic facial erythema and telangiectasias, sometimes papulopustular.

== Medicines used for Rosacea ==

<problemMedicines slug="rosacea" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Rheumatoid Arthritis

2026-06-13T06:04:42Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Rheumatoid Arthritis ==

<problemMedicines slug="rheumatoid-arthritis" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Restless Legs Syndrome

2026-06-13T06:04:40Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Restless Legs Syndrome ==

<problemMedicines slug="restless-legs-syndrome" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Rejection Sensitivity Dysphoria

2026-06-13T06:04:38Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Rejection Sensitivity Dysphoria ==

<problemMedicines slug="rejection-sensitivity-dysphoria" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Recreational use

2026-06-13T06:04:37Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Use of a medicine outside an approved medical indication for its subjective effects. Documented here as a real use category, without endorsement.

== Medicines used for Recreational use ==

<problemMedicines slug="recreational-use" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Public speaking anxiety

2026-06-13T06:04:35Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Situational anxiety around public speaking or performance.

== Medicines used for Public speaking anxiety ==

<problemMedicines slug="public-speaking" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Psoriatic Arthritis

2026-06-13T06:04:33Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Psoriatic Arthritis ==

<problemMedicines slug="psoriatic-arthritis" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Psoriasis

2026-06-13T06:04:32Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Chronic immune-mediated scaling skin disease.

== Medicines used for Psoriasis ==

<problemMedicines slug="psoriasis" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Pruritus

2026-06-13T06:04:30Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Itching, generalized or localized.

== Medicines used for Pruritus ==

<problemMedicines slug="itch" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Premenstrual Dysphoric Disorder

2026-06-13T06:04:28Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Premenstrual Dysphoric Disorder ==

<problemMedicines slug="premenstrual-dysphoric-disorder" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Premature ejaculation

2026-06-13T06:04:26Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Premature ejaculation ==

<problemMedicines slug="premature-ejaculation" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Postural Orthostatic Tachycardia Syndrome

2026-06-13T06:04:25Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Postural Orthostatic Tachycardia Syndrome ==

<problemMedicines slug="postural-orthostatic-tachycardia-syndrome" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Posttraumatic Stress Disorder

2026-06-13T06:04:23Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Posttraumatic Stress Disorder ==

<problemMedicines slug="posttraumatic-stress-disorder" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Polycystic Ovary Syndrome

2026-06-13T06:04:21Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Polycystic Ovary Syndrome ==

<problemMedicines slug="polycystic-ovary-syndrome" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Persistent Depressive Disorder (Dysthymia)

2026-06-13T06:04:19Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Persistent Depressive Disorder (Dysthymia) ==

<problemMedicines slug="persistent-depressive-disorder-dysthymia" />

[[Category:Problems]]
[[Category:Problem stubs]]